Afleveringen
-
Get up to date on menin inhibitors, an emerging class of targeted therapies for acute myeloid leukemia (AML). Menin is a key component of the KMT2A (lysine methyltransferase 2A, formerly MLL1) complex, which plays a critical role in gene regulation, development, and cell cycle control. Small-molecule menin inhibitors have shown particular promise in KMT2A-rearranged (KMT2Ar) and NPM1-mutated AML, with two agents already receiving FDA breakthrough therapy designation.
In this episode, Dr Scott Armstrong and Prof Marc Raaijmakers explore the scientific rationale behind menin inhibition, identify which AML patient populations are most likely to benefit, and review the current clinical evidence supporting their use in defined molecular subtypes.
Guests:âŻ
Dr Scott Armstrong
Dana-Farber Cancer Institute
Prof Marc Raaijmakers
Erasmus Medical Center
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
â â â â â â â Provide Feedbackâ â â â â â â
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
â â â â â â â https://ehaedu.org/Campusâ â â â â â â
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: â â â â â â â https://www.instagram.com/EHA_Hematology/â â â â â â â
Facebook: â â â â â â â https://e-h-a.link/facebookâ â â â â â â
LinkedIn: â â â â â â â https://www.linkedin.com/company/eha/â â â â â â â
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via â â â â â â â https://eha.news/subscribeâ â â â â â
-
GetâŻup to dateâŻwithâŻthe EHAâESMO guidelines on Human immunodeficiency virus (HIV)-associated Lymphomas.
In this episode, Prof. Kai Hubel, a key author of the guidelines, explains the importance of having dedicated recommendations for patients with HIV-associated lymphomas. He begins by discussing the prevalence of lymphomas in people living with HIV, then highlights that the modern CART HIV treatment should be combined with the lymphoma treatments.
This interview further provides practical guidance to navigate these detailed recommendations that cover key lymphoma subtypes including DLBCL, Burkitt lymphoma, plasmatic lymphoma, and more.
Finally, Prof Hubel advocates for the inclusion of people living with HIV in lymphoma clinical trials to increase evidence base on HIV-associated lymphomas and improve the care for this specific patient populations.
Link to the guideline:âŻHuman immunodeficiency virusâassociated Lymphomas: EHAâESMO Clinical Practice Guideline for diagnosis, treatment and followâup - HĂŒbel - 2024 - HemaSphere - Wiley Online Library
Guest:⯠Prof Kai HĂŒbel
Department of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
â â â â â â Provide Feedbackâ â â â â â
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
â â â â â â https://ehaedu.org/Campusâ â â â â â
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: â â â â â â https://www.instagram.com/EHA_Hematology/â â â â â â
Facebook: â â â â â â https://e-h-a.link/facebookâ â â â â â
LinkedIn: â â â â â â https://www.linkedin.com/company/eha/â â â â â â
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via â â â â â â https://eha.news/subscribeâ â â â â â
-
Zijn er afleveringen die ontbreken?
-
Join Meritxell Alberich JordĂ , an EHA Board member and a principal investigator from Prague, as she shares her journey to becoming a recognised research scientist in hematology, and the role EHA has played along the way. Her lab studies hematopoietic and leukemic stem cells, focusing on how disruptions in transcriptional regulation and inflammatory signalling drive the development and persistence of acute myeloid leukemia.
Meri reflects on how her early research interests evolved over time, how key career decisions shaped the questions she pursues today, and what she finds most rewarding about leading a lab. Tune in to hear what she wishes sheâd known at the very beginning of her journey.
Guest: Associate Prof Meritxell Alberich JordĂ
Institute of Molecular Genetics of the Czech Academy of Sciences, Laboratory of Haematooncology Head, Prague, Czech Republic The Childhood Leukaemia Investigation Prague in the Department of Pediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
â â â Provide Feedbackâ â â
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
â â â https://ehaedu.org/Campusâ â â
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: â â â https://www.instagram.com/EHA_Hematology/â â â
Facebook: â â â https://e-h-a.link/facebookâ â â
LinkedIn: â â â https://www.linkedin.com/company/eha/â â â
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via â â â https://eha.news/subscribeâ â â
-
GetâŻup to dateâŻwithâŻthe latestâŻEHA Clinical Practice Guidelines for Large B-cell lymphoma (LBCL) (â Large Bâcell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and followâup - Thieblemont - 2025 - HemaSphere - Wiley Online Library).â
Prof Catherine Thieblemont and Prof Marie JosĂ© Kersten, two key authors of the guidelines, âŻwalk us through the recommendations for Large B-cell lymphoma, covering diagnosis, treatment, and follow-up.
Gain insights into key diagnostic considerations including staging, biopsy techniques and the importance of molecular testing. Our guests explain treatment strategies for first-line and relapse/refractory patient populations, highlighting the practice-changing introduction of CAR T therapy in second-line for eligible patients. Finally, they discuss the disparities of access to innovative treatments across Europe and explore future perspectives of LBCL management in Europe and beyond.
Guests:âŻProf Catherine Thieblemont and Prof Marie JosĂ© Kersten.
Professor Catherine Thieblemont from Saint-Louis Hospital in Paris.
Professor Marie José Kersten from Amsterdam University Medical Centers (UMC)
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
â â â â â Provide Feedbackâ â â â â
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
â â â â â https://ehaedu.org/Campusâ â â â â
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: â â â â â https://www.instagram.com/EHA_Hematology/â â â â â
Facebook: â â â â â https://e-h-a.link/facebookâ â â â â
LinkedIn: â â â â â https://www.linkedin.com/company/eha/â â â â â
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via â â â â â https://eha.news/subscribeâ â â â â
-
In this episode of EHA Unplugged, patient advocate Peter Kapitein discusses the importance of connecting patients, researchers, and clinicians to accelerate cancer research and treatment. He shares insights from his work with Inspire2Live, focusing on collaboration, data ownership, affordability, and global access to innovative therapies.
Guest: Peter Kapitein
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
â â â â â â Provide Feedbackâ â â â â â
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
â â â â â â https://ehaedu.org/Campusâ â â â â â
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: â â â â â â https://www.instagram.com/EHA_Hematology/â â â â â â
Facebook: â â â â â â https://e-h-a.link/facebookâ â â â â â
LinkedIn: â â â â â â https://www.linkedin.com/company/eha/â â â â â â
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via â â â â â â https://eha.news/subscribeâ â â â â â
Guest: Peter Kapitein
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
â â â â Provide Feedbackâ â â â
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
â â â â https://ehaedu.org/Campusâ â â â
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: â â â â https://www.instagram.com/EHA_Hematology/â â â â
Facebook: â â â â https://e-h-a.link/facebookâ â â â
LinkedIn: â â â â https://www.linkedin.com/company/eha/â â â â
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via â â â â https://eha.news/subscribeâ â â â
-
Get up to date with the latest ESMO-EHA guideline for Peripheral T- and natural killer-cell lymphomas (Peripheral Tâ and natural killerâcell lymphomas: ESMOâEHA Clinical Practice Guideline for diagnosis, treatment, and followâup - d'Amore - 2025 - HemaSphere - Wiley Online Library) Prof Francesco D'Amore (Aarhus University, Denmark) and Prof Massimo Federico (University of Modena and Reggio Emilia, Italy).
In this episode, two key authors of the guidelines walk us through the recommendations for these rare, biologically diverse, and often aggressive- peripheral T cell and NK cell lymphomas.
Our guests explain the conscious effort of the guidelines panel to provide evidence based detailed recommendations for each subtype of PTCLs to improve diagnosis, treatment, and follow up. The emphasis is on moving away from âone size fits allâ DLBCL style approach toward entity- adapted strategies.
Throughout the conversation, they stress the need to read the full guideline â including the supplementary material â and the importance of a multidisciplinary approach by experienced hematopathologists, ideally in expert or reference centres to give patients the best chance of appropriate, modern therapy.
GuestS: Prof Francesco D'Amore and Prof Massimo Federico.
Professor Francesco D'Amore is a Clinical Professor and Chair of the Department of Hematology at Aarhus University in Denmark
Professor Massimo Federico is a Senior Professor of Medical Oncology at the University of Modena and Reggio Emilia in Italy
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
â â â Provide Feedbackâ â â
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
â â â https://ehaedu.org/Campusâ â â
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: â â â https://www.instagram.com/EHA_Hematology/â â â
Facebook: â â â https://e-h-a.link/facebookâ â â
LinkedIn: â â â https://www.linkedin.com/company/eha/â â â
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via â â â https://eha.news/subscribeâ â â
-
Join EHA President⯠Prof âŻKonstanze Döhner⯠from âŻUniversity Hospital UlmâŻinâŻGermany as she discusses her deep interest inâŻhematology, both in research and in the clinics.âŻ
ListenâŻas⯠Prof.âŻDöhner shares why she decided to focus on Acute Myeloid Leukemia (AML) and myeloproliferative neoplasms (MPNs) in her career as a medical doctor, a researcher and a educator.âŻâŻTune in to hear⯠Prof.âŻDöhner describe her journey to becoming the EHA president and her reflections on the current challenges in the hematology field and the solutions she proposes to address those.
Guest: Prof Konstanze Döhner, University Hospital Ulm, GermanyâŻ
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
â â Provide Feedbackâ â
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
â â https://ehaedu.org/Campusâ â
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: â â https://www.instagram.com/EHA_Hematology/â â
Facebook: â â https://e-h-a.link/facebookâ â
LinkedIn: â â https://www.linkedin.com/company/eha/â â
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via â â https://eha.news/subscribeâ â
-
In this episode, Dr Michael Milsom discusses how thehematopoietic system aging is a complex process with multiple causes. Dr Milsom proposes a more holistic view of the driving mechanisms of hematopoietic andimmune aging that does not focus solely on HSCs. He describes how inflammationâdriven stem cell activation and proliferation cause functional attrition and clonalselection of HSCs, contributing to clonal hematopoiesis.
Learn about the mechanisms of blood cells aging andpotential interventions to slow down the process.
Guest: Dr Michael Milsom
Head of the Division of Experimental Hematology at the German Cancer Research Center, (DKFZ), and group leader at the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HIâSTEM), Heidelberg, Germany
Host: Isabel Olivera Martinez, PhD
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
â Provide Feedbackâ
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
â https://ehaedu.org/Campusâ
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: â https://www.instagram.com/EHA_Hematology/â
Facebook: â https://e-h-a.link/facebookâ
LinkedIn: â https://www.linkedin.com/company/eha/â
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via â https://eha.news/subscribeâ
-
Get up to date with the latest EHA-EU guideline for Mantle Cell Lymphoma (EHAâEU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library) with Prof Mats Jerkeman (Lund University, Sweden).
In this episode, he explains how biological risk factors, particularly TP53 mutations and proliferation rate, inform patient stratification. He reviews evolving treatment sequencing, including the expanding role of BTK inhibitors (such as ibrutinib) in first-line regimens.
He further discusses the management relapsed/refractory MCL, where BTK inhibitors and CAR T-cell therapy have largely supplanted but not fully replaced allogeneic transplantation.
Throughout the conversation, Prof Jerkeman emphasizes the dynamic evolution of MCL treatment and the need for ongoing guideline updates as new evidence emerges.
Link to the guideline: (EHAâEU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library)
Link to Lund University:
Mats Jerkeman - Lund University
Home | Lund University
Learn More
Interested in more content related to CART? We've got you covered. Check out free CART program on â EHA Campusâ .
What did you think of this podcast? Share your opinions with us in this short feedback survey.
â Provide Feedbackâ
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
â https://ehaedu.org/Campusâ
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: â https://www.instagram.com/EHA_Hematology/â
Facebook: â https://e-h-a.link/facebookâ
LinkedIn: â https://www.linkedin.com/company/eha/â
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via â https://eha.news/subscribeâ
-
[This is a Rerelease. Episode first published on July 19, 2024.]Join us for a conversation with Jonathan Clark, a patient advocate who has been in remission for over five years after receiving CAR T-cell therapy for Mantle Cell Lymphoma.
Jonathan shares his journey from relapse to recovery, detailing the challenges and triumphs of this cutting-edge treatment from a patientâs perspective. With host Dr. Sarah de Vlieger, they discuss his motivation for sharing his story and the profound physical and psychological impacts of long-term remission.
Jonathan also talks about managing long-term side effects like immunodeficiencies and how apparently small changes can significantly improve quality of life. He emphasizes the importance of understanding the patient's perspective, advocating for quality of life improvements, and the need for personalized care that goes beyond medical statistics. Jonathan highlights the global disparities in accessing advanced treatments like CAR T-cell therapy and concludes with a call to prioritize quality of life in treatment decisions.
Host: Dr Sarah de Vlieger
Guest: Jonathan Clark
This episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024.
Learn More
Interested in more content related to CART? We've got you covered. Check out free CART program on â EHA Campusâ .
What did you think of this podcast? Share your opinions with us in this short feedback survey.
â Provide Feedbackâ
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
â https://ehaedu.org/Campusâ
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: â https://www.instagram.com/EHA_Hematology/â
Facebook: â https://e-h-a.link/facebookâ
LinkedIn: â https://www.linkedin.com/company/eha/â
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via â https://eha.news/subscribeâ
-
[This is a Rerelease. Episode first published on November 22, 2024.]Join us in this podcast episode to get a glimpse of what the future holds in the big field of innovation in hematology. With the help of our host, Dr Gregor Hormann (MLL Munich Leukemia Laboratory, Germany), you will be taken on a journey toward a future that is already here.
Dr Hormann will discuss the many potentials of AI in hematology and oncology, including the automated integrated diagnostic tools, from morphology to chromosomal banding analysis in a few minutes, new classification algorithms, and innovative large language models (LLMs) assisting physicians in the diagnosis prediction.
The take-home message? "AI will not replace physicians. However, physicians who use AI will replace those who don't."
Host: Dr Wilson Lim
Guest: Dr Gregor Hormann
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
â Provide Feedbackâ
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
â https://ehaedu.org/Campusâ
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: â https://www.instagram.com/EHA_Hematology/â
Facebook: â https://e-h-a.link/facebookâ
LinkedIn: â https://www.linkedin.com/company/eha/â
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via â https://eha.news/subscribeâ
-
[This is a Rerelease. Episode first published on November 1, 2024.]
Join us for an engaging episode with Dr. Stephen Hibbs from Queen Mary University of London as he discusses the environmental impacts of hematology. Alongside our host Dr. Sarah de Vlieger, they explore how climate change is already affecting hematology, emphasizing that these effects are being felt now rather than in the future.
The conversation highlights how climate change alters aspects of hematology practice, such as the risk of transfusion-transmitted infections due to evolving disease vectors. Dr. Hibbs describes also the surprising link between extreme heat during pregnancy and an increased risk of children developing ALL (acute lymphoblastic leukemia). He further discusses practice-changing initiatives, like using sevoflurane instead of desflurane as an anesthetic to reduce environmental impact, and explains his work on improving the logistics of blood transfusions to lessen their ecological footprint.
Finally, Dr. Hibbs encourages hematologists to focus on actionable steps to minimize their environmental impact, advocating for practical changes in clinical practices and increased awareness of the healthcare sector's contribution to global emissions.
Host: Dr Sarah de Vlieger
Guest: Dr Stephen Hibbs
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
â Provide Feedbackâ
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
â https://ehaedu.org/Campusâ
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: â https://www.instagram.com/EHA_Hematology/â
Facebook: â https://e-h-a.link/facebookâ
LinkedIn: â https://www.linkedin.com/company/eha/â
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via â https://eha.news/subscribeâ
-
[This is a Rerelease. Episode first published on April 11, 2025.]
Listen to Dr. Jan Moritz Middeke from University Hospital in Dresden as he discusses the future of clinical trials in hematology and the role artificial intelligence (AI) may play in that field.
Dr. Middeke explains how synthetic data is generated and what are the potential benefits and limitations of its use in clinical trials. He also points out the open questions and hurdles that need to be addressed before AI-generated synthetic patients can be included in clinical trial design.
Tune in to hear how Dr. Middeke envisages the role of AI in solving the challenges of clinical trials for rare malignant diseases and how it may accelerate data generation and access to novel therapies.
If you want to know more:
â https://www.nature.com/articles/s41746-024-01076-xâ
Host: Isabel Olivera-Martinez, PhD, Medical WriterâŻ
Guest: Dr. Jan Moritz Middeke
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
â https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1â
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
â https://ehaedu.org/Campusâ
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: â https://www.instagram.com/EHA_Hematology/â
Facebook: â https://e-h-a.link/facebookâ
LinkedIn: â https://www.linkedin.com/company/eha/â
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via â https://eha.news/subscribeâ
-
Join us for this interview with Dr RĂo-MachĂn from Autonomous University of Madrid in Spain as she discusses her research on rare subtypes of acute myeloid leukemia (AML), which she conducted thanks to the EHA Junior Research Grant.
Her discovery of transcriptional activator of key leukemia drivers in one of these subtypes may pave way to new therapeutic approaches.
Tune in to hear dr. RĂo-MachĂnâs call for more collaborative research to achieve impactful results for patients in the future.
Host: Isabel Olivera-Martinez, PhD, Medical WriterâŻ
Guest: Dr Ana RĂo-MachĂn
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
-
Join us for this discussion between Prof Argiris Symeonidis from University of Patras in Greece and Prof Sam Salek from University of Hertfordshire in UK who focus on the role of the hematologist in the diagnosis and management of patients with Gaucher disease.
Prof Symeonidis and Prof Salek are both experts in recognizing and treating this rare lysosomal storage disorder and share their recommendations for hematologists to ensure earlier detection of this disease.
Host: Prof. Sam Salek, University of Hertfordshire, UK
Guest: Prof. Argiris Symeonidis, University of Patras, Rion, Greece
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
-
Join us for this inspiring interview with Erik Aerts from University Hospital Zurich in Switzerland and MairĂ©ad NĂ Chonghaile from St. Jamesâs Hospital in Ireland who discuss their extensive work within the Hematology Nurses & Healthcare Professionals Group (HNHCP).
Erik, the President, and Mairéad, the Vice-President of HNHCP, describe their unwavering commitment to providing hematology education to nurses and other healthcare professionals to ensure the best possible care for their patients. Tune in to hear what their thoughts are on the future of nursing in hematology and how they envisage addressing its biggest challenges.
Host: Isabel Olivera-Martinez, PhD, Medical WriterâŻ
Guests:
Erik Aerts, Nurse Manager, University Hospital Zurich, Switzerland and President of Hematology Nurses & Healthcare Professionals Group (HNHCP)
MairĂ©ad NĂ Chonghaile, Bone Marrow Transplant Coordinator, St. Jamesâs Hospital, Dublin, Ireland and Vice-President of HNHCP
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
-
Join us for this inspiring interview with prof. JesĂșs San-Miguel from ClĂnica Universidad de Navarra in Spain who discusses his extensive work to improve care for patients with multiple myeloma.
Prof San-Miguelâs research and clinical contributions have shaped the current treatment landscape for multiple myeloma.
For his contributions, he has received the 2025 EHA Lifetime Achievement Award. Tune in to hear his thoughts about the future of multiple myeloma management and the crucial role that collaborative research will play in it.
Host: Isabel Olivera-Martinez, PhD, Medical WriterâŻ
Guest: Prof JesĂșs San-Miguel, ClĂnica Universidad de Navarra, Spain
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
-
Join us for this interview with Dr Mandy Lauw from Erasmus Medical Center in Rotterdam, Netherlands who describes her work to increase the visibility and voice of young hematologists within the EHA.
For her unwavering efforts to improve the support and opportunities for young hematologists at the beginning of their career, Dr Lauw has been awarded the Young EHA Award.
Tune in to hear about the many educational and mentoring programs EHA has available for young hematologists.
Host: Isabel Olivera-Martinez, PhD, Medical WriterâŻ
Guest: Dr Mandy Lauw
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
-
Join us for this interview with Dr Ferran Nadeu Prat from August Pi i Sunyer Biomedical Research Institute in Barcelona, Spain who discusses his work on evolution of chronic lymphocytic leukemia (CLL), which he conducted thanks to the EHA Junior Research Grant.
Dr Nadeu Prat explains how the new insights into CLL evolution toward Richter transformation, which is a lethal complication of CLL, may lead to new therapeutic approaches.
Tune in to hear his views on the future of this field and the role of collaborative research in achieving these goals.
Host: Isabel Olivera-Martinez, PhD, Medical WriterâŻ
Guest: Dr Ferran Nadeu Prat, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
-
Join us for this conversation with prof. Mariane de Montalembert from Necker-Enfants Malades Hospital in France who discusses the current standards of care for patients with sickle cell disease and thalassemia, both in Europe and in sub-Saharan Africa.
Prof. de Montalembert highlights the inequalities and the unique challenges in implementation of complex innovative treatments, such as gene therapy.
Tune in to hear her thoughts on the possible solutions for these challenges and future directions in this field.
Host: Isabel Olivera-Martinez, PhD, Medical WriterâŻ
Guest: Prof Mariane de Montalembert, Necker-Enfants Malades Hospital, Paris, France
Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
- Laat meer zien
